• Telomir Pharmaceuticals posted a net loss of USD 990,947 for quarter ended March 31, 2026, narrowing from USD 2.18 million a year earlier.
• Total operating costs fell to USD 1.04 million from USD 2.19 million, led by general and administrative expense dropping to USD 573,539 from USD 1.85 million.
• Research and development expense rose to USD 467,797 from USD 336,996, while total other income increased to USD 50,389 from USD 7,954 on higher interest income of USD 51,644.
• Cash and cash equivalents totaled USD 5.6 million at March 31, 2026; operating cash outflow widened to USD 1.77 million from USD 863,132.
• FDA cleared an IND to start a Telomir-Zn trial in advanced or metastatic triple-negative breast cancer; company expects cash to fund operations through first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023010), on May 14, 2026, and is solely responsible for the information contained therein.